Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas

D. V. Jones, S. M. Sugarman, A. B. Markowitz, B. Levin, J. L. Abbruzzese, D. B. Evans, C. Charnsangavej, R. Smith, Y. Z. Patt

    Research output: Contribution to journalArticle

    Abstract

    Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8%). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.

    Original languageEnglish (US)
    Pages (from-to)1121-1123
    Number of pages3
    JournalOncology Reports
    Volume2
    Issue number6
    StatePublished - Jan 1 1995

      Fingerprint

    Keywords

    • 5-fluorouracil
    • Chemotherapy
    • Cisplatin
    • Drug synergy
    • Leucovorin
    • Pancreatic cancer

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Jones, D. V., Sugarman, S. M., Markowitz, A. B., Levin, B., Abbruzzese, J. L., Evans, D. B., Charnsangavej, C., Smith, R., & Patt, Y. Z. (1995). Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. Oncology Reports, 2(6), 1121-1123.